Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial
European Journal of Cancer · 2024-09 · 209 · 114276
DOI: 10.1016/j.ejca.2024.114276 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2024-09. Verfasst von Vincenzo Nasca und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fondazione IRCCS Istituto Tumori Milano, Milan, Italy. Hauptthemen laut MEDLINE: Sunitinib, Pheochromocytoma, Paraganglioma, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Pfizer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Fondazione IRCCS Istituto Tumori Milano, Milan, Italy.
- Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Diagnostic Pathology and Laboratory Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Radiology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Sarcoma and Rare Tumors Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Naples, Italy; ENETs Center of Excellence, Naples, Italy.
- Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, ENETS Center of Excellence, Milan, Italy.
Förderung
- Pfizer
Zitieren
APA
Nasca, V., Prinzi, N., Coppa, J., Prisciandaro, M., Oldani, S., Ghelardi, F., Conca, E., Capone, I., Busico, A., Perrone, F., Tamborini, E., Sabella, G., Greco, G., Greco, F. G., Tafuto, S., Procopio, G., Morano, F., Niger, M., Maccauro, M., …, & Pusceddu, S. (2024). Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial. European Journal of Cancer, 209, 114276. https://doi.org/10.1016/j.ejca.2024.114276
Vancouver
Nasca V, Prinzi N, Coppa J, Prisciandaro M, Oldani S, Ghelardi F, et al. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial. European Journal of Cancer. 2024;209:114276. doi:10.1016/j.ejca.2024.114276
BibTeX
@article{Nasca2024,
author = {Nasca, Vincenzo and Prinzi, Natalie and Coppa, Jorgelina and Prisciandaro, Michele and Oldani, Simone and Ghelardi, Filippo and Conca, Elena and Capone, Iolanda and Busico, Adele and Perrone, Federica and Tamborini, Elena and Sabella, Giovanna and Greco, Giorgio and Greco, Francesca Gabriella and Tafuto, Salvatore and Procopio, Giuseppe and Morano, Federica and Niger, Monica and Maccauro, Marco and Milione, Massimo and de Braud, Filippo and Pietrantonio, Filippo and Pusceddu, Sara},
title = {Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial},
journal = {European Journal of Cancer},
year = {2024},
volume = {209},
pages = {114276},
doi = {10.1016/j.ejca.2024.114276}
}
EUVIMED